Navigation Links
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Date:3/11/2009

New use for PEGINTRON(TM) and REBETOL(R) offers certain patients a second chance to achieve treatment success

KENILWORTH, N.J., March 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved new labeling for PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for treating chronic hepatitis C in patients 3 years of age and older with compensated liver disease. With approval of this expanded indication, PEGINTRON and REBETOL is the first and only pegylated interferon combination therapy approved in the United States that is not restricted to treatment-naive patients. Patients less likely to benefit from retreatment after failing a course of therapy include those with previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, or HCV genotype 1 infection. It is estimated that more than 100,000 patients in the United States failed prior treatment of their hepatitis C virus (HCV) infection, representing a large and growing patient population.

"With the FDA approval of PEGINTRON and REBETOL combination therapy for this new indication, U.S. physicians now have a treatment option that offers a second chance for success to certain patients who failed prior therapy," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "This approval further underscores Schering-Plough's leadership and long-term commitment to developing new treatment options and innovative therapies to meet the needs of patients with hepatitis C."

Data from the clinical study supporting the approval helped to define those patient groups most likely to respond to retreatment as well as those unlikely to respond. Overall, p
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... analysts and managers to,visualize and collaborate across ... real-time, SCOTTSDALE, Ariz., April 28 ... C4 Systems, introduces CoMotion(R) Trials, a,collaborative, decision-support ... and managers to see, analyze, share and ...
... DENVER, April 28 The Colorado Cancer,Research Program (CCRP) invites ... Golf Tournament on May 19 at the Valley Country Club,14601 ... Denver,s,premier golf courses and has been the home to major ... boast that two of its professional,golfers have been inducted into ...
Other Medicine Technology:New CoMotion(R) Trials Software by General Dynamics Enables Rapid, Interactive Sharing of Real-time Data for Clinical Trials 2Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer 2Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer 3
(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...
(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...
(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...
Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Cleft lip/palate cause much more than cosmetic problems 2
... Association to raise funds,through in-store ,pin-up, campaign, ALEXANDRIA, ... announced that Kmart has reinforced its,commitment to ADA and ... National Strategic Partner (NSP). As a National Strategic,Partner, Kmart ... mission to,prevent and cure diabetes, and to improve the ...
... to have active are:,Anthony Leiserowitz ... New Haven, Conn. A growing number of Americans ... action, and 40% say that a presidential candidates position on ... a national survey conducted by Yale University, Gallup and the ...
... 1, 2007 - When a child is farsighted or ... bilateral amblyopia may develop. In contrast to single-eye amblyopia ... image to the brain, bilateral amblyopia affects both eyes ... the October issue of the American Journal of Ophthalmology, ...
... 1, 2007 Newer ultrasound and magnetic resonance ... diagnosing fibrosis (scarring) and cirrhosis of the liver, ... of the journal Clinical Gastroenterology and Hepatology. , ... techniques may reduce the need for biopsiesprocedures done ...
... chance of trouble down the road, study says , , MONDAY, Oct. ... of TV, turn it off now and save yourself a lot ... that suggests that the negative effects of lots of early TV ... age of 6. , The study doesn,t confirm that television is ...
... assess the stability of three aspects of sleep behavior ... of mortality in short sleep, long sleep and frequent ... the October 1 issue of the journal SLEEP. , ... the Finnish Institute of Occupational Health in Helsinki, Finland, ...
Other Medicine News:Health News:Kmart Steps Out to Fight Diabetes 2Health News:Kmart Steps Out to Fight Diabetes 3Health News:Americans consider global warming an urgent threat, according to poll 2Health News:Early treatment of children with bilateral amblyopia essential, according to multisite study 2Health News:Noninvasive tests for cirrhosis may help to avoid liver biopsy 2Health News:Noninvasive tests for cirrhosis may help to avoid liver biopsy 3Health News:Kids' TV Viewing Tied to Behavioral Problems 2Health News:Kids' TV Viewing Tied to Behavioral Problems 3Health News:Both short and long sleep is associated with increased mortality 2
... The ReSeeVit 5Z slit lamp is ... video imaging. This video-ready slit lamp ... source. It is another addition to ... that offers the best products on ...
The AIA-600 II has become the new standard in benchtop immunoassay analyzers....
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
Remote Control Vision Tester Can Administer Basic,Distance Vision Tests in Less Than 2 Minutes....
Medicine Products: